Radiopharmaceutical company Lantheus Holdings is reportedly considering a possible sale after receiving a takeover offer from private equity-backed Curium Pharma that values the company at around $7 billion, according to a Bloomberg News report published on Friday.
The report stated that both companies have been discussing a potential deal that could be finalized within the coming weeks, citing sources familiar with the matter. However, no final decision has been reached yet, and there is no assurance that the discussions will lead to an official transaction.
Lantheus Holdings declined to comment on the report. Shares of the company, which currently has a market value of around $6.15 billion, were down nearly 2% in after-hours trading.
According to the report, Curium Pharma was valued at approximately $7 billion last year when its owner, CapVest Partners, raised funding for a continuation vehicle linked to the nuclear medicine company. Curium did not immediately respond to Reuters’ request for comment.
Earlier this month, Lantheus Holdings reported first-quarter adjusted profit that exceeded analysts’ expectations, supported by strong demand for its cancer imaging products.
“2026 is a year of commercial execution and regulatory milestones,” said interim CEO Mary Heino on the earnings call. “We’re making deliberate choices about where we focus our commercial efforts and deploying capital, so we’re positioned to deliver solid results in 2026 and accelerate growth in 2027.”
Lantheus Holdings maintained its full-year earnings forecast. However, according to a William Blair analyst, the company acknowledged that an upward revision to its guidance may be warranted, though it is unlikely to happen until a permanent CEO is appointed.
In March, the U.S. Food and Drug Administration extended its review of Lantheus’ diagnostic imaging kit, LNTH-2501, by an additional three months to allow more time for evaluating manufacturing-related details. A final decision is now expected by June 29.
Also in March, the regulator approved a new formulation of the company’s prostate cancer imaging agent, Pylarify, which is intended to expand patient access to scanning services by increasing production capacity.
